Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study

Abdoli, Asghar; Aalizadeh, Reza; Aminianfar, Hossein; Kianmehr, Zahra; Emamipour, Nabbi; Jamshidi, Hamid Reza; Hosseinpour, Mitra; Taqavian, Mohammad; Jalili, Hasan

doi:10.1101/2021.06.10.447951

Cited by 14 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CovIran Barekat is an inactivated whole virus vaccine against Sars-Cov-2 manufactured by the Shifapharmed Industrial Group Company in Iran. The animal trial result, published as a preprint, shows that this vaccine can induce an immune response with adequate safety in mice, rabbits, and non-human primates [56]. Study protocols were registered in the Iranian Registry of Clinical trials (IRCT20201202049567N1, IRCT20201202049567N2, and IRCT20201202049567N3).…”

Section: Vaccines Profilementioning

confidence: 99%

COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran

Vaezi

Meysamie

2021

Vaccines

View full text Add to dashboard Cite

COVID-19 vaccines are supposed to be critical measure for ending the pandemic. Governments had to decide on the type of vaccine to provide for their population. In this decision-making process, cost-effectiveness analysis is considered a helpful tool. This study is a cost-effectiveness analysis utilized to calculate the incremental cost per averted disability-adjusted life year (DALY) by vaccination compared to no vaccination for different COVID-19 vaccines. The incremental cost-effectiveness ratio (ICER) for a vaccination with COVID-19 vaccines was estimated at 6.2 to 121.2 USD to avert one DALY and 566.8 to 10,957.7 USD per one death. The lowest and highest ICERs belong to Ad26.COV2.S and CoronaVac, respectively. Considering the scenario of Iran, vaccines that are recommended include ad26.cov2.s, chadox1-S, rAd26-S + rAd5-S, and BNT162b2 in the order of recommendation.

show abstract

Section: Vaccines Profilementioning

confidence: 99%

COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran

Vaezi

Meysamie

2021

Vaccines

View full text Add to dashboard Cite

show abstract

“…Inactivated SARS-CoV-2 vaccines based on inactivated viruses such as COVIran Barekat may have better efficacy against variants that have mutations in the spike protein. 96 Similar to AstraZeneca, Sinovac, and Sinopharm developed vaccines, COVIran Barekat should be kept at 2-8 º C. It has been reported that this vaccine is about 93% effective in COVID-19 prevention. 97 COVIran Barekat is well tolerated in two doses (5 µg) of intramuscular injection.…”

Section: Coviran Barekatmentioning

confidence: 99%

The Medication Therapies and Existing COVID-19 Vaccines, the Nature of Manufacture, and the Degree of Immunity

Eslami Farsani,

Heidari,

Ababzadeh

et al. 2023

Int J Basic Sci Med

View full text Add to dashboard Cite

The globe is currently dealing with one of the worst epidemics, SARS-CoV-2. The various drugs can treat the clinical symptoms of SARS-CoV-2, and combination therapies may be more effective than monotherapy. This study discussed various COVID-19 subtypes, pharmaceutical effectiveness, the advantages and disadvantages of medications, and mortality rates in various countries. The drugs were reviewed as well. The macrolides family can produce anti-inflammatory cytokines against COVID-19, but they may cause side effects such as bacterial resistance. Although anti-malarial drugs may inhibit the entrance of the virus into cells, they are not a common medicine in COVID-19 treatment. The simultaneous consumption of corticosteroids with other drugs can be beneficial for high-intensity patients. In addition, remdesivir may be effective in severe cases of the disease. However, the administration of several drugs can be more effective compared to a single drug. Although pharmacological combinations can be effective in treating SARS-CoV-2, vaccines are considered to be the most successful approach for reducing COVID-19. Pfizer/ BioNTech and Moderna vaccines are based on the mRNA of viruses and provide an efficiency of about 95%. Sputnik V was prepared by two replication-incompetent adenovirus vectors. The AstraZeneca–Oxford vaccine was prepared based on viral vectors, and its efficacy has a variable range of 62%–90%. The vaccines based on an inactivated virus provided innate immunity in the body. Soberana 2 is a recombinant vaccine. Generally, all vaccines may have positive effects on the prevention of COVID-19, but further clinical trials are necessary. These findings suggest each available vaccine is advised for protection against COVID-19.

show abstract

“…Alum adjuvant was utilized in the formulation of COVIran Barekat to achieve an effective and robust immune response. 45 In phase 1 clinical trial (IRCT20201202049567N1), the vaccine was evaluated on 56 healthy volunteers with the age range of 18–55 years, which led to satisfactory safety and immune response. In the second phase 1 clinical trial (IRCT20201202049567N2), the evaluation of the vaccine was started in a smaller population, that is, 32 healthy adults aged 51–75 years.…”

Section: Coviran Barekat Vaccinementioning

confidence: 99%

“…SARS‐CoV‐2 virus culture on Vero monolayers cells and then virus particles were inactivated using PBL. Alum adjuvant was utilized in the formulation of COVIran Barekat to achieve an effective and robust immune response 45 . In phase 1 clinical trial (IRCT20201202049567N1), the vaccine was evaluated on 56 healthy volunteers with the age range of 18–55 years, which led to satisfactory safety and immune response.…”

Section: Coviran Barekat Vaccinementioning

confidence: 99%

An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines

Khoshnood

Arshadi

Akrami

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

After about 2 years since severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), first infections were detected in Wuhan city of China in December 2019, which was followed by a worldwide pandemic with a record of 5.41 million deaths. Due to urgent need for the development of a safe and effective vaccine for coronavirus disease 2019 (COVID‐19), attempts for producing efficient vaccines are inexhaustibly continuing. According to a report by the World Health Organization (WHO) on COVID‐19 vaccine tracker and landscape, there are 149 vaccine candidates all over the world. Inactivated SARS‐CoV‐2 vaccines as a conventional vaccine platform consist of whole virus particles grown in cell culture and inactivated by chemicals. Because of benefits such as antigenic similarity to real virion inducing humoral and cellular immune responses and ease for transport and storage, these vaccines, including the vaccines produced by Bharat Biotech, Sinopharm, and Sinovac, are in use at large scales. In this study, we have a review on inactivated SARS‐CoV‐2 vaccines that are passing their phase 3 and 4 clinical trials, population which was included in the trials, vaccine producers, the efficiency, adverse effects, and components of vaccines, and other vaccine features.

show abstract

Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study

Cited by 14 publications

References 40 publications

COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran

COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran

The Medication Therapies and Existing COVID-19 Vaccines, the Nature of Manufacture, and the Degree of Immunity

An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines

Contact Info

Product

Resources

About